Premium
Effect of the Market Withdrawal of Carisoprodol on Use of Other Prescribed Drugs With Abuse Potential
Author(s) -
Bramness J G,
Furu K,
Skurtveit S,
Engeland A
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.250
Subject(s) - muscle relaxant , clinical pharmacology , addiction , medicine , medical prescription , substance abuse , drug , pharmacology , psychiatry , anesthesia
Carisoprodol, a centrally acting muscle relaxant indicated for acute lower back pain, has been available in Europe and the United States since 1959. Studies indicating increased risk of abuse or addiction led to withdrawal of the drug from the market in Norway and other EU countries in 2008. In this nationwide longitudinal prescription study of 53,116 individuals in Norway, previous users of carisoprodol switched, to a limited extent, to other prescribed drugs with abuse potential after the withdrawal. Clinical Pharmacology & Therapeutics (2012); 91 3, 438–441. doi: 10.1038/clpt.2011.250